Gelteq announced today that it received a U.S. patent for its GTT Gel product for testing human response to oral glucose loads.
Melbourne, Australia-based Gelteq designed its GTT Gel diabetes diagnostic system for use in pathology labs and at-home testing through a proprietary gel-based delivery system.
The tests take blood samples from patients at different time intervals (ranging from zero to two hours after drinking a measured dose of a glucose solution) to detect diabetes, insulin resistance or other disorders of glucose metabolism.
Based on Gelteq’s technology that can “gelify” a wide range of ingredients to create an easily ingestible formulation for many applications, the platform can offer benefits for diabetes diagnostic testing, including masking the strong sugar taste of test ingredients, reducing the volume needed to be consumed, creating a more accurate dosage and supporting better absorption in the gastrointestinal system.
Gelteq said in a news release that it plans to launch a mobile diabetes screening kit in the U.S. in the first quarter of 2022, making it available to hospitals, labs, medical centers and pharmacies around the country.
“This U.S. patent provides strong protection for our revolutionary gel technology and our highly differentiated gel science, particularly for the critical field of diabetes testing,” Gelteq CEO Nathan Givoni said in the release. “Early diagnosis of prediabetes or diabetes is crucial for the best treatment and outcomes, and patient compliance and testing accuracy are key. Our GTT Gel addresses this need in a unique way that is superior to traditional approaches.”
